Autologous stem cell transplantation for adults with
Philadelphia-negative acute lymphoblastic leukemia in first
complete remission. A study by the Acute Leukemia Working Party
of the EBMT

J 2025

Autologous stem cell transplantation for adults with Philadelphia-negative acute lymphoblastic leukemia in first complete remission. A study by the Acute Leukemia Working Party of the EBMT

SWOBODA, Ryszard; Myriam LABOPIN; Sebastian GIEBEL; Johan MAERTENS; Elena PAROVICHNIKOVA et al.

Základní údaje

Originální název

Autologous stem cell transplantation for adults with Philadelphia-negative acute lymphoblastic leukemia in first complete remission. A study by the Acute Leukemia Working Party of the EBMT

Autoři

Vydání

BMC Cancer, London, BioMed Central, 2025, 1471-2407

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30205 Hematology

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 3.400 v roce 2024

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/25:00143847

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

Autologous stem cell transplantation; Philadelphia negative acute lymphoblastic leukemia; Complete remission

Štítky

14110212, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 3. 3. 2026 12:12, Mgr. Tereza Miškechová

Anotace

V originále

Background: The role of autologous hematopoietic stem cell transplantation (AHSCT) in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia (Ph-ALL) remains controversial. The aim of this retrospective study was to analyze results of AHSCT and to identify prognostic factors. Methods: Overall, 700 patients transplanted in first complete remission between the years 1999-2020 were included. Median patient age was 31.9 years (68% male). B-cell precursor ALL (BCP-ALL) and T-cell precursor ALL (TCP-ALL) was diagnosed in 35% and 65%, respectively. Among 190 patients with available data, negative minimal residual disease (MRD) status was reported in 167 (88%) cases. Results: The probabilities of overall survival (OS) and leukemia-free survival (LFS) at 2 years were 67% and 56%; relapse incidence (RI) and non-relapse mortality (NRM) were 39% and 5%, respectively. TCP-ALL was associated with lower RI (41% vs. 56%, p=0.001), higher LFS (52% vs. 38%, p=0.002) and OS (58% vs 45%, p=0.001) at 5 years when compared to BCP-ALL. In the multivariate analysis, TCP-ALL and longer interval from diagnosis do AHSCT were associated with reduced risk of relapse (HR 0.7, p=0.006 and HR=0.95, p=0.018), better LFS (HR=0.76, p=0.02 and HR=0.95, p=0.01) and OS (HR=0.75, p=0.024 and HR=0.94, p=0.013, respectively). Increasing patient age was associated with higher NRM (HR=1.49, p<0.0001), worse LFS (HR=1.1, p=0.01) and OS (HR=1.17, p=0.0001). Conclusions: Autologous hematopoietic stem cell transplantation is relatively safe option of late treatment intensification in adults with Ph- ALL. It may be a valuable option especially in patients with TCP-ALL, however it should be proved in prospective clinical trials.

Citovat

SWOBODA, Ryszard; Myriam LABOPIN; Sebastian GIEBEL; Johan MAERTENS; Elena PAROVICHNIKOVA; Jurjen VERSLUIS; Jiri PAVLU; Anna KOPINSKA; Saveria CAPRIA; Ludek RAIDA; Alessandro RAMBALDI; Denis CAILLOT; František FOLBER; David NACHBAUR; Mustafa OZTURK; Mahmoud ALJURF; Marie Therese RUBIO; Norbert Claude GORIN; Francesco LANZA; Arnon NAGLER; Mohamad MOHTY a Fabio CICERI. Autologous stem cell transplantation for adults with Philadelphia-negative acute lymphoblastic leukemia in first complete remission. A study by the Acute Leukemia Working Party of the EBMT. BMC Cancer. London: BioMed Central, 2025, roč. 25, č. 1, s. 1-12. ISSN 1471-2407. Dostupné z: https://doi.org/10.1186/s12885-025-14126-8.

@article{2558043,
   author = {Swoboda, Ryszard and Labopin, Myriam and Giebel, Sebastian and Maertens, Johan and Parovichnikova, Elena and Versluis, Jurjen and Pavlu, Jiri and Kopinska, Anna and Capria, Saveria and Raida, Ludek and Rambaldi, Alessandro and Caillot, Denis and Folber, František and Nachbaur, David and Ozturk, Mustafa and Aljurf, Mahmoud and Rubio, Marie Therese and Gorin, Norbert Claude and Lanza, Francesco and Nagler, Arnon and Mohty, Mohamad and Ciceri, Fabio},
   article_location = {London},
   article_number = {1},
   doi = {https://doi.org/10.1186/s12885-025-14126-8},
   keywords = {Autologous stem cell transplantation; Philadelphia negative acute lymphoblastic leukemia; Complete remission},
   language = {eng},
   issn = {1471-2407},
   journal = {BMC Cancer},
   title = {Autologous stem cell transplantation for adults with Philadelphia-negative acute lymphoblastic leukemia in first complete remission. A study by the Acute Leukemia Working Party of the EBMT},
   url = {https://link.springer.com/article/10.1186/s12885-025-14126-8},
   volume = {25},
   year = {2025}
}

TY  - JOUR
ID  - 2558043
AU  - Swoboda, Ryszard - Labopin, Myriam - Giebel, Sebastian - Maertens, Johan - Parovichnikova, Elena - Versluis, Jurjen - Pavlu, Jiri - Kopinska, Anna - Capria, Saveria - Raida, Ludek - Rambaldi, Alessandro - Caillot, Denis - Folber, František - Nachbaur, David - Ozturk, Mustafa - Aljurf, Mahmoud - Rubio, Marie Therese - Gorin, Norbert Claude - Lanza, Francesco - Nagler, Arnon - Mohty, Mohamad - Ciceri, Fabio
PY  - 2025
TI  - Autologous stem cell transplantation for adults with Philadelphia-negative acute lymphoblastic leukemia in first complete remission. A study by the Acute Leukemia Working Party of the EBMT
JF  - BMC Cancer
VL  - 25
IS  - 1
SP  - 1-12
EP  - 1-12
PB  - BioMed Central
SN  - 14712407
KW  - Autologous stem cell transplantation
KW  - Philadelphia negative acute lymphoblastic leukemia
KW  - Complete remission
UR  - https://link.springer.com/article/10.1186/s12885-025-14126-8
N2  - Background: The role of autologous hematopoietic stem cell transplantation (AHSCT) in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia (Ph-ALL) remains controversial. The aim of this retrospective study was to analyze results of AHSCT and to identify prognostic factors. Methods: Overall, 700 patients transplanted in first complete remission between the years 1999-2020 were included. Median patient age was 31.9 years (68% male). B-cell precursor ALL (BCP-ALL) and T-cell precursor ALL (TCP-ALL) was diagnosed in 35% and 65%, respectively. Among 190 patients with available data, negative minimal residual disease (MRD) status was reported in 167 (88%) cases. Results: The probabilities of overall survival (OS) and leukemia-free survival (LFS) at 2 years were 67% and 56%; relapse incidence (RI) and non-relapse mortality (NRM) were 39% and 5%, respectively. TCP-ALL was associated with lower RI (41% vs. 56%, p=0.001), higher LFS (52% vs. 38%, p=0.002) and OS (58% vs 45%, p=0.001) at 5 years when compared to BCP-ALL. In the multivariate analysis, TCP-ALL and longer interval from diagnosis do AHSCT were associated with reduced risk of relapse (HR 0.7, p=0.006 and HR=0.95, p=0.018), better LFS (HR=0.76, p=0.02 and HR=0.95, p=0.01) and OS (HR=0.75, p=0.024 and HR=0.94, p=0.013, respectively). Increasing patient age was associated with higher NRM (HR=1.49, p<0.0001), worse LFS (HR=1.1, p=0.01) and OS (HR=1.17, p=0.0001). Conclusions: Autologous hematopoietic stem cell transplantation is relatively safe option of late treatment intensification in adults with Ph- ALL. It may be a valuable option especially in patients with TCP-ALL, however it should be proved in prospective clinical trials.
ER  -

SWOBODA, Ryszard; Myriam LABOPIN; Sebastian GIEBEL; Johan MAERTENS; Elena PAROVICHNIKOVA; Jurjen VERSLUIS; Jiri PAVLU; Anna KOPINSKA; Saveria CAPRIA; Ludek RAIDA; Alessandro RAMBALDI; Denis CAILLOT; František FOLBER; David NACHBAUR; Mustafa OZTURK; Mahmoud ALJURF; Marie Therese RUBIO; Norbert Claude GORIN; Francesco LANZA; Arnon NAGLER; Mohamad MOHTY a Fabio CICERI. Autologous stem cell transplantation for adults with Philadelphia-negative acute lymphoblastic leukemia in first complete remission. A study by the Acute Leukemia Working Party of the EBMT. \textit{BMC Cancer}. London: BioMed Central, 2025, roč.~25, č.~1, s.~1-12. ISSN~1471-2407. Dostupné z: https://doi.org/10.1186/s12885-025-14126-8.

Přehled o publikaci